搜尋
Agenus Inc
AGEN添加自選
3.490USD
+0.080+2.35%
收盤 07/02, 13:00（美東）報價延遲15分鐘
134.44M總市值
1.69本益比TTM
關鍵數據
3.400今開
3.515最高
680.58K成交量
1.69本益比TTM
虧損本益比動
--股利TTM
1.77%換手率
3.410昨收
3.370最低
1.71M成交額
虧損本益比靜
-0.61市淨率
0.00%股息率 TTM
32.32%ROA
7.34052週最高
0.72量比
-227.43M淨利潤
38.52M總股本
2.0638每股盈餘TTM
1.58Beta
-556.54%ROE
2.71052週最低
4.25%振幅
100.00%毛利率
134.44M總市值
0.09回報/風險
5.00%風險率
TradingKey Agenus Inc股票評分
單位: USD 更新時間: 2026-07-02操作建議
Agenus Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名125/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為15.50。中期看，股價處於下降通道。近一個月，市場表現一般，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Agenus Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Agenus Inc亮點
亮點風險
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
估值高估
公司最新PE估值1.69，處於3年歷史高位
機構減倉
最新機構持股10.91M股，環比減少8.15%
分析師目標
基於
2
分析師
買入
評級
15.500
目標均價
+354.55%
漲幅空間
Agenus Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Agenus Inc簡介
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
公司代碼AGEN
公司Agenus Inc
CEOArmen (Garo H)
網址https://agenusbio.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52867.000
+14.100 (+0.03%)
29724.900
+55.000 (+0.18%)
7514.800
+7.000 (+0.09%)
14966.000
+3.000 (+0.02%)
69566.000
-110.000 (-0.16%)
6412.600
+0.200 (+0.00%)
68.274
-0.409 (-0.59%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4184.090
+9.480 (+0.23%)
常見問題
Agenus Inc(AGEN)的當前股價是多少？
Agenus Inc(AGEN)的當前股價是 3.49。
Agenus Inc 的股票代碼是什麼？
Agenus Inc的股票代碼是AGEN。
Agenus Inc股票的52週最高點是多少？
Agenus Inc股票的52週最高點是7.34。
Agenus Inc股票的52週最低點是多少？
Agenus Inc股票的52週最低點是2.71。
Agenus Inc的市值是多少？
Agenus Inc的市值是134.44M。
現在Agenus Inc(AGEN)的股票是買入、持有還是賣出？
根據分析師評級，Agenus Inc(AGEN)的總體評級為買入，目標價格為15.50。
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是多少
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是-0.00。